Mostrando 2 resultados de: 2
Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck
ArticleAbstract: The prognosis of patients with advanced head and neck cancer remain dismal. For this tumor type, elePalabras claves:Epidermal growth factor receptor, immunotherapy, Monoclonal antibody, nimotuzumab, Squamous cell carcinoma of the head and neck, Targeted therapyAutores:Alert J., Bahi R.D.C., Bárbara Wilkinson, Bilbao M.A., Carmen Elena Viada, De Armas E.L., Frómeta M., Galainena J.J., Gracias E., Iznaga N., Leonard I., Luaces P.L.o., Muchuli C.R., Mulén B., Mullens V., Pérez K., Pineda I., Rivero T.C., Rodríguez E., Rodríguez M.O., Tania Crombet, Torres O., Vinageras E.N.Fuentes:scopusPharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: A SENDO Foundation study
ArticleAbstract: Purpose: To assess the pharmacodynamic effects of nimotuzumab, an anti-epidermal growth factor recepPalabras claves:Autores:Albanell J., Bellosillo B., Campas C., Cedeño M., Corominas J.M., Corradino I., Cruz T., Gascon P., Gracias E., Iznaga N., Marsoni S., Osorio M., Rojo F., Rovira A., Serrano S., Sessa C., Tania Crombet, Villena N.Fuentes:scopus